Fujifilm buys Biogen biologics unit for $890 million

Mar 12, 2019

Fujifilm has announced plans to buy U.S.-based drugmaker Biogen's biologics unit for approximately $890 million. According to the Japanese company the acquisition is meant to shore up its healthcare business.

The unit includes biologics manufacturing operations in Hillerød, Denmark and about 800 employees, which will continue working under Fujifilm. The operations contain bioreactors that can produce blockbuster drugs or biosimilars that need mass production.

Last year the Fujifilm said it would buy two biotechnology units from JXTG Holdings Inc for about $800 million.

According to Fujifilm, it expects this transaction to be completed in August. 

This latest unit is Fujifilm's fourth and will still produce drugs for Biogen after the deal.

Read the full release.

Want to get content like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments